Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$42.93 USD

42.93
1,631,798

-1.74 (-3.90%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $42.92 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EXAS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Exact Sciences Corporation [EXAS]

Reports for Purchase

Showing records 261 - 280 ( 366 total )

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 261

05/02/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 262

05/02/2013

Company Report

Pages: 7

1Q13 - Heading to PMA Filing and NCD Submission

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 263

05/01/2013

Company Report

Pages: 9

1Q13 Recap - Positive New Comments On Pre-Cancer Sensitivity Variances & Superiority to FIT

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 264

04/19/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 265

04/18/2013

Company Report

Pages: 5

DeeP-C Results Reported

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 266

04/18/2013

Company Report

Pages: 8

Warming Up Slightly, Given Sell-Off - Attractive Clinical Utility & Sizable End Market Remains - Less FDA Risk vs. Our Initial Read - PT to $10

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 267

04/18/2013

Company Report

Pages: 9

Pivotal Data Misses on Pre-Cancer Sensitivity (42% vs. expectations >50%) - Conf. Call at 7:30 am - PT & Rating Under Review Pending Mgmt Comments

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 268

04/11/2013

Daily Note

Pages: 9

Charts & Thoughts in Front of Pivotal Data - Maintaining NEUTRAL Rating

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 269

04/03/2013

Industry Report

Pages: 9

Healthcare - 1Q 2013: Quarterly Medical Technology Trading & Acquisition Update

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 270

04/01/2013

Industry Report

Pages: 13

Healthcare - Notes from the Podium: Med Tech Highlights from the 2013 Roth OC Conference

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 50.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 271

03/15/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 272

03/14/2013

Company Report

Pages: 11

DeeP-C Pivotal Data Release Imminent- A Preview & Analysis of Outcomes

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 273

02/21/2013

Company Report

Pages: 8

4Q12 - Focus on DeeP-C Data Release & Commercial Development

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 274

02/21/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 275

02/21/2013

Company Report

Pages: 9

4Q12 Results In-line - Clinical Trial & FDA Schedule On Track

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 276

02/19/2013

Company Report

Pages: 8

4Q12 Surprises Unlikely - Expecting In-Line Results - FDA Submission Schedule on Track - FDA & CMS Dialogue Plus IBD Trial in Focus

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 277

01/14/2013

Industry Report

Pages: 8

Healthcare -4Q 2012: Quarterly Medical Technology Trading & Acquisition Update

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 278

12/20/2012

Daily Note

Pages: 8

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 279

12/20/2012

Company Report

Pages: 39

We are initiating coverage with a Buy rating and a 12-month price target of $16.

Provider: Roth Capital Partners, Inc.

Analyst: DOLAN M

Price: 75.00

Research Provided by a Third Party

Company: Exact Sciences Corporation

Industry: Medical - Biomedical and Genetics

Record: 280

10/31/2012

Company Report

Pages: 5

REITS BUY DEMONSTRATING PROGRESS TOWARD COLOGUARD FDA APPROVAL.

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party